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Abstract 
The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with 
reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of 
patients) and associated with a higher risk of HF hospitalization, all-cause and 
cardiovascular (CV) mortality. The most important causes of HF in T2DM are 
coronary artery disease, arterial hypertension and a direct detrimental effect of T2DM 
on the myocardium. T2DM is often unrecognized in HF patients, and vice versa, 
which emphasizes the importance of an active search for both disorders in the 
clinical practice. There are no specific limitations to HF treatment in T2DM. 
Subanalyses of trials addressing HF treatment in the general population have shown 
that all HF therapies are similarly effective regardless of T2DM. Concerning T2DM 
treatment in HF patients, most guidelines currently recommend metformin as the 
first-line choice. Sulphonylureas and insulin have been the traditional second- and 
third-line therapies although their safety in HF is equivocal. Neither glucagon-like 
preptide-1 (GLP1) receptor agonists, nor dipeptidyl peptidase-4 (DPP4) inhibitors 
reduce the risk for HF hospitalization. Indeed, a DPP4 inhibitor, saxagliptin has been 
associated with a higher risk of HF hospitalization. Thiazolidinediones (pioglitazone 
and rosiglitazone) are contraindicated in patients with (or at risk of) HF. In recent 
trials, sodium glucose cotransporter-2 (SGLT2) inhibitors, empagliflozin and 
canagliflozin, have both shown a significant reduction in HF hospitalization in patients 
with established CV disease or at risk of CV disease. Several ongoing trials should 
provide an insight into the effectiveness of SGLT2 inhibitors in patients with HFrEF 
and HFpEF in the absence of T2DM. 
Key words: heart failure, type 2 diabetes, heart failure hospitalization, heart failure 
treatment, glucose lowering agents 
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Introduction 
The coexistence of heart failure (HF) and type-2 diabetes mellitus (T2DM) is common 
and has a strong impact on clinical management and prognosis. T2DM is associated 
with worse clinical status and increased all-cause and cardiovascular (CV) mortality 
in both patients with HF with reduced (HFrEF) and preserved ejection fraction 
(HFpEF), compared to HF patients without T2DM (1). Conversely, HFrEF is an 
independent predictor of fatal and non-fatal clinical outcomes in patients with T2DM 
(2, 3). The major causes of HF in T2DM include coronary artery disease (CAD) and 
hypertension, but also, a possible direct detrimental effect of T2DM on the 
myocardium (4). This position paper provides advice and education pertinent to the 
clinical management of patients with T2DM and HF. The document summarizes the 
epidemiology and current understanding of the mechanisms underlying the 
intersection between T2DM and HF. It further presents contemporary treatment 
options for patients with established T2DM and HF, and summarizes recent evidence 
of HF prevention with drugs used to treat T2DM.  
Epidemiology 
Prevalence of T2DM and HF in general populations 
The prevalence of T2DM, which encompasses 90-95% of diabetic individuals, has 
globally increased from 4.7% in 1980 to 8.5% in 2014 (5), albeit diagnostic criteria 
have changed over that period (6, 7). Contemporary data suggest a stable overall HF 
prevalence of 11.8% (range 4.7-13.3%) in the general population (8) .   
The prevalence of HF in patients with T2DM 
In the Reykjavik study in the general population, the prevalence of HF in people with 
T2DM was 12% (9). In this study, HF was more common in patients with T2DM >70 
years (i.e. 16% and 22% of men and women, respectively). In the Kaiser Permanente 
population, patients with T2DM <75 years had an approximately 3-fold higher 
prevalence of HF compared to those without T2DM (10). In those aged 75-84 years, 
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T2DM was associated with a doubling of risk for HF. In these relatively old studies, 
HF phenotype (i.e. HFrEF or HFpEF) or biomarker status was not reported. In clinical 
trials of T2DM patients, the prevalence of HF at baseline has varied between 
approximately 10% and 30% (Table 1).  
The prevalence of T2DM in patients with HF 
In the general population, HF is associated with a higher prevalence of T2DM 
compared to patients without HF (Table 2), but marked regional differences have 
been observed both in Europe and in rest of the world. In studies conducted in 
Iceland (9) and Italy (11), T2DM prevalence was 4 and 3 times higher, respectively, 
whereas in Italy, T2DM prevalence was almost doubled in HF subjects (Table 2). 
Approximately 25% of patients with HF in England (12) and Denmark (13) also had 
T2DM. Despite younger age and less obesity, a significantly higher prevalence of 
T2DM (57%) was observed in a population-based cohort of Southeast Asian HF 
patients compared to Caucasian patients (24%) (14). The reasons for the wide 
regional variation in T2DM prevalence in HF patients warrants further international 
studies with shared study design and standardized data collection.  
In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, 
irrespective of HF phenotype (i.e. HFrEF and HFpEF) (Table 3). The highest 
prevalence of T2DM was seen in trials of acute HF (around 40%). 
In registries of hospitalized HF patients in North America and Europe, the prevalence 
of T2DM is around 40-45% (15-18), and a slight increase in the prevalence was 
reported in the North America over time (15, 18). In the Swedish HF Registry, Swed-
HF, (68% from hospitals and 32% from primary care) T2DM was more prevalent in 
HF patients with CAD compared to those without (30% versus 19%, respectively) 
(19). 
The incidence of new T2DM in patients with HF 
In patients with HF, data from observational and clinical trials demonstrate an 
increased risk for new-onset T2DM compared to patients without HF. In a Kaiser 
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Permanente study, the incidence of T2DM was significantly higher in patients with 
than without HF (i.e. 13.6/1000 versus 9.2/1000) over a 5 year follow-up (10). In a 
Danish nation-wide cohort study, 8% of HF patients developed T2DM over 3 years, 
and the severity of HF was associated with a stepwise increased risk of developing 
T2DM (20). Similar incidence of T2DM was reported in clinical trials of HF patients, 
as demonstrated by the CHARM program, in which 7.8% of patients developed 
T2DM over 2.8 years (21, 22). In the EMPHASIS trial including HFrEF patients, the 
incidence of T2DM was 3.7% over a median follow-up of 21 months (23). Notably, 
HF treatment with angiotensin converting enzyme (ACE) inhibitors was shown to 
lower the incidence of T2DM in HFrEF patients; in a substudy of the SOLVD trial, 6% 
of patients in the enalapril arm developed T2DM over a mean follow-up of 2.9 years 
as opposed to 22% in the placebo arm (24). Registry data corroborate that the use of 
renin-angiotensin system inhibitors is associated with attenuated risk for T2DM in HF 
patients receiving loop diuretics (20). Clinical trials also demonstrated that the 
severity of HF, as indicated by a higher New York Heart Association (NYHA) class, 
increases the likelihood of developing T2DM (11, 25). 
The incidence of HF in patients with T2DM 
Recently, a population-based study of 1.9 million patients with T2DM without overt 
CV disease, followed for 5.5 years, demonstrated that incident HF was observed 
more frequently (14.1%), than vascular events including myocardial infarction (MI) or 
stroke (26). T2DM is an independent risk factor for the development of HF (10). In a 
retrospective cohort followed for up to 72 months, patients with T2DM were more 
likely to develop HF than patients without T2DM (incidence rate 30.9 versus 
12.4/1,000 person-years, rate ratio 2.5) (27). In elderly patients with T2DM, the 
incidence of HF was 2-fold higher compared to patients without T2DM (121 vs. 62 
cases/1000 patient-years) (28). In UKPDS trial including newly diagnosed diabetic 
patients, HF incidence steeply increased with the severity of dysglycaemia ranging 
from 2.3 to 11.9/1000 person-years for patients with HbA1c <6% and HbA1c >10%, 
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respectively (29). Similarly, in the observational studies, NHANES (30) and ARIC 
(31), the incidence of HF in patients with T2DM was higher than in those without 
T2DM, with the corresponding hazard ratios (HRs) of 1.85 and 3.54. Indeed, in the 
ARIC study, higher HbA1c levels in T2DM patients were associated with significantly 
more incident HF cases than in patients with T2DM and lower HbA1c levels (31). The 
incidence of HF in T2DM patients compared to those without T2DM is even higher in 
patients with established CAD, in which each 1% increase in HbA1c level was 
associated with a 36% increased risk for HF hospitalization (32, 33). Patients with 
pre-diabetes in the ARIC study also had more HF than those without pre-diabetes 
(34). 
T2DM, clinical status and outcomes in patients with HF 
Clinical presentation, quality of life and functional status of patients with T2DM 
and HF 
Patients with T2DM and both HFrEF (1, 35-37) and HFpEF (1) have worse NYHA 
functional class and more HF-related symptoms and signs than patients without 
T2DM, despite having similar ejection fraction (36, 37). In the SOLVD-Prevention trial 
of patients with asymptomatic left ventricular systolic dysfunction (LVSD), patients 
with T2DM were more likely to progress to symptomatic HF than those without 
T2DM, although the increased risk appeared to be confined to patients with HF 
secondary to CAD (38).  
Most trials also demonstrated worse quality of life in patients with T2DM and 
concurrent HF (both HFrEF and HFpEF), as compared to patients without T2DM (36, 
39). Patients with T2DM and HFrEF also have shorter 6-minute walk distances and 
decreased peak oxygen uptake in comparison to non-diabetics (21, 36, 40).   
T2DM and mortality in patients with HF 
In all population-based studies, T2DM was associated with increased all-cause 
mortality in HF patients, albeit substantial regional differences were reported across 
Europe, and no differentiation between HFrEF and HFpEF was performed (Table 4). 
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In Sweden, there was a moderately higher risk (HR, 1.60) (19) and in the 
Netherlands a significantly higher risk of death (HR, 3.19) (41) attributed to T2DM. 
Additionally, in the Rotterdam study, T2DM was associated with an excess risk for 
CV death (HR, 3.25) that was similar to the risk of all-cause mortality (41). Likewise, 
all studies of the effect of T2DM on mortality in HF outpatients have found a higher 
mortality risk attributable to T2DM (Table 4). 
Concerning patients hospitalized for HF, data on the association between T2DM and 
in-hospital mortality are divergent. In the OPTIMIZE, ADHERE and Get With the 
Guidelines-HF registries in the United States, T2DM was not associated with a higher 
in-hospital mortality (42-45). Conversely, in the ALARM registry (six European 
countries, Mexico and Australia), and in the ESC-HF-Long Term Registry, T2DM was 
independently associated with a higher risk of in-hospital mortality (17, 46). There is 
a suggestion from some cohorts (42, 47) that short term mortality in HF patients post 
discharge may be similar or slightly lower in those with T2DM. However, with longer-
term follow-up, an association between T2DM and worse outcomes in HF patients 
becomes evident. For example, in the EVEREST trial in which patients were followed 
for 9.9 months after a HF hospitalization, T2DM conferred a slightly higher mortality 
(48). Also, in patients from Scotland, T2DM increased mid-to-long term mortality  
following hospitalization for HF (47). Likewise, in the ESC-HF Long Term Registry, 
the presence of T2DM was independently associated with increased 1-year all-cause 
mortality (17, 49). 
Clinical trial results are somewhat conflicting regarding the risk of all-cause and CV 
mortality attributed to T2DM in HF patients, but most clinical trials reported an 
increased risk of death in patients with concurrent T2DM and HF. In HFrEF, 7 out of 
11 trials demonstrated an association between T2DM and increased all-cause 
mortality, with the reported HRs between 1.3 and 2.0 (mostly around 1.5) (Table 5). 
Also 3 HFrEF trials reported increased CV death, with HRs between 1.5 and 1.8 (1, 
50, 51). Concerning HFpEF, all trials reported increased all-cause mortality (HRs, 1.5 
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to 1.8) and 2 out of 4 trials also reported an increased risk of CV mortality in patients 
with T2DM compared to patients without T2DM, with HRs 1.6 to 1.9 (Table 5). In the 
CHARM trial, T2DM was an independent risk factor for both all-cause mortality and 
CV mortality even after adjustment for 32 co-variates (1). Additionally, in the same 
study, T2DM had a greater association with higher all-cause and CV mortality in 
patients with HFpEF than HFrEF (1).  
A recent meta-analysis of 31 registries and 12 clinical trials with 381,725 patients 
with acute and chronic HF, with a median follow-up of 3 years confirms that T2DM is 
independently associated with a higher risk of all-cause death (random-effects HR, 
1.28), CV death (HR, 1.34), hospitalization (HR, 1.35), and the combined end point of 
all-cause death or hospitalization (HR, 1.41), and the observed long term risk 
appears greater in patients with chronic than in those with acute HF (52). 
T2DM and causes of death in patients with HF 
In the CHARM trial, patients with T2DM and both HFrEF and HFpEF were more likely 
to die of all subtypes of CV death (i.e. death due to HF, sudden cardiac death, death 
due to MI and death due to stroke) (1). The PARADIGM study also reported that 
patients with T2DM and HFrEF were more likely to die of CV as well as all-cause 
mortality compared with patients without T2DM (36). In the BEST trial, T2DM was an 
independent risk factor for death from pump failure (53). 
Aside from CV death, results from the Emerging Risk Factors Collaboration, including 
820,900 people, demonstrate that T2DM is independently associated with increased 
risk of death from several cancers (i.e. liver, pancreas, ovary, colorectum, lung, 
bladder, and breast), renal and liver disease, pneumonia and other infectious 
diseases, mental and nervous-system disorders, nonhepatic digestive diseases, 
external causes, and chronic obstructive pulmonary disease (54). The study found 
that a 50-year-old with T2DM died, on average, 6 years earlier than an individual 
without T2DM, with about 40% of the difference in survival attributable to excess 
nonvascular deaths (54). 
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Is the higher risk of T2DM only seen in HF secondary to CAD? 
Whether or not the increased risk of mortality with T2DM in HF patients is seen in 
both those of ischemic and non-ischemic etiology is uncertain. The majority of the 
available data suggests that T2DM is associated with higher risk of mortality in both 
patients of ischemic and non-ischemic aetiology (Table 6). In a population-based 
Danish study, which followed patients for 6.8 years, patients with T2DM and HF had 
higher mortality whether or not they had CAD (55). The higher risk appeared early 
and persisted throughout follow-up. In the CHARM trial, patients with both HFrEF and 
HFpEF had higher mortality attributed to T2DM whether or not they had CAD (1). In 
the DIAMOND trial, T2DM was associated with a higher risk of mortality in both 
ischemic and non-ischemic HF (56). These consistent findings conflict with 2 smaller 
population-based studies in the United States (57) and France (58) and one Spanish 
single-center study (59) of patients hospitalized with HF which suggested that DM 
was only associated with higher mortality in those with non-ischemic etiology.  In 3 
early clinical trials (SOLVD (60), BEST (53), and DIG (61)) the risk appeared to be 
confined to those with an ischemic etiology.  
Is the higher risk of mortality with T2DM and HF seen in both women and men? 
An early report from the Framingham study reported that the mortality risk related to 
T2DM was confined to women and not to men (62). In 2 population-based studies 
from Scotland and Sweden, the increased mortality risk of T2DM was seen in both 
women and men, but the effect was slightly greater in women (47, 55). Likewise, in 
the recent ESC-HF Long Term Registry and in the CHARM trial, T2DM was a risk 
factor for mortality in both men and women (1, 49). 
Does HbA1c predict mortality in patients with HF and T2DM? 
In the CHARM trial, high HbA1c was associated with increased all-cause and CV 
mortality in patients with T2DM and both HFrEF and HFpEF (63). A 1% increase in 
HbA1c was associated with an increased HR of 1.1 for CV mortality (63). In patients 
from a US study of HF clinics, a U-shaped relationship with regards to increased all-
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cause mortality was found (38). Patients with either very low or very high HbA1c 
were at greatest risk. A similar U-shaped curve was found in a single-center study 
from Scotland (64). In one single center observational study of 123 young patients 
with advanced HF and T2DM, patients with a HbA1c of <7% had higher rates of all-
cause mortality (65). In the GISSI-HF study, including 6935 chronic HF patients, the 
presence of T2DM and higher HbA1c levels were independent predictors of all-cause 
mortality (HRs, 1.43 and 1.21, respectively) and the composite outcome of mortality 
and CV hospitalization (HRs, 1.21 and 1.14) (66). 
In summary, high HbA1c levels in T2DM and HF are consistently associated with 
higher mortality. Conversely, low HbA1c levels can be associated with good 
outcomes (at least in a clinical trial cohort), but can be associated with worse 
outcomes (in population-based studies and those with very advanced HF).  
Pre-diabetes and undiagnosed T2DM and risk of mortality in HF 
In the PARADIGM-HF trial, patients with pre-diabetes were at increased risk of 
mortality (36). Patients with undiagnosed T2DM were also at higher risk of mortality 
than subjects without T2DM, but the risk was not as high as in patients with 
previously known T2DM. In the CHARM, pre-diabetes and undiagnosed T2DM were 
both associated with greater rates of HF hospitalization, CV and all-cause mortality 
than those without T2DM (67). However, not all studies have reported an increased 
mortality risk with pre-diabetes. In a study of 970 non-diabetic patients with HF, an 
increased 1-year mortality risk was found only in patients with HbA1c >6.7% and 
reduced left ventricular ejection fraction (LVEF) ≤45%, but not in those with HFpEF 
(68). Also, in the GISSI-HF study of unselected HF patients, pre-diabetes was not an 
independent predictor of increased mortality (66). The reasons behind these 
discrepancies might be attributed to differences in patient characteristics and warrant 
further assessment. 
T2DM and risk for HF hospitalization 
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Several clinical trials documented that patients with T2DM and HFrEF were more 
likely than patients without T2DM to be hospitalized for HF (1, 36, 37, 53, 69). In the 
CHARM trial, rates of hospitalization for HF in patients with T2DM were greater for 
those with HFpEF than HFrEF and patients with HFpEF and T2DM were almost 2.5 
times more likely to be hospitalized for HF than those without T2DM (1). In I-
PRESERVE, patients with T2DM and HFpEF were also more likely to be hospitalized 
with HF (39). 
Readmission after a hospitalization for HF 
Registry data indicate that patients with T2DM had more all-cause re-hospitalizations 
than those without T2DM (42, 70, 71). In a population-based study in Scotland, 
T2DM was a predictor of readmission for HF (with the increased risk greatest in 
younger women) (47). In the ESC-HF Long Term Registry, T2DM was independently 
associated with re-hospitalizations for HF (17). Likewise, in the EVEREST trial, 
T2DM was associated with greater rates of HF re-hospitalization (HR, 1.19) (48). 
In addition, as demonstrate by the OPTIMIZE and Get With The Guidelines 
Registries in the United States, patients with HF and T2DM experience slightly longer 
hospitalizations than patients without T2DM (42-44).   
T2DM, myocardial infarction and stroke in patients with HF 
The only trial to investigate the association between T2DM and risk of MI and stroke 
in HF patients was the CHARM trial demonstrating that the presence of T2DM 
increased the risk for MI and stroke irrespective of HF phenotype (i.e. HFrEF or 
HFpEF) (1).   
Risk for HF hospitalization in patients with T2DM without a previous history of 
HF 
In the ARIC registry, representing a cohort of 14,079 people in the community without 
known HF, T2DM was the most powerful risk factor for incident HF hospitalization 
(70). In a large meta-analysis of patients with T2DM but without HF, predictors of 
incident HF include insulin use, HbA1c and fasting glucose (72).  
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Mortality in T2DM patients with HF 
In the CV outcomes trials of new therapies for T2DM, the development of HF is 
associated with markedly higher mortality (especially in RECORD (73) and SAVOR-
TIMI (74)). Patients with T2DM who developed HF had a 10 to 12 times greater 
mortality than those who did not develop HF (3)(75). In addition, they are also at a 
2.45-fold greater risk of CV death compared with patients with T2DM but without HF 
(76). 
Unrecognized HF in patients with T2DM and unrecognized T2DM in patients 
with HF 
Observational evidence indicates that a significant proportion of patients aged ≥60 
years (27.7%) may have unrecognized HF (22.9% and 4.8%, HFpEF and HFrEF, 
respectively) based on the ESC diagnostic criteria (77, 78). On the other hand, pre-
diabetes and undiagnosed T2DM are common in patients with HF. In the PARADIGM 
trial, 13% of patients with HFrEF had undiagnosed T2DM and 25% had pre-diabetes 
(36). Likewise, 11% of “non-T2DM” patients with HFrEF in the RESOLVD trial had 
undiagnosed T2DM (79). In the CHARM study, undiagnosed T2DM was common in 
both HFrEF and HFpEF (67). In the ESC-HF-Long Term Registry, even higher 
proportion of HF patients (19.1%) had undiagnosed T2DM (49). 
Considering prognostic implications of concurrent T2DM and HF, these findings 
stress the importance of developing screening strategies for unrecognized HF among 
T2DM patients and vice versa. Since evidence is sparse of strategies for HF 
screening (78), in T2DM patients, screening for HF might be currently based on 
clinical characteristics (i.e. age, history of CAD, exercise-related shortness of breath, 
body mass index, laterally displaced apex beat) that have been shown to reliably 
identify elderly subjects at risk of HF that may require further assessment (e.g. 
echocardiography) (80). Such a strategy may be used to prevent complications and 
possibly improve outcomes, particularly in subjects with HFrEF (81). Conversely, 
since undiagnosed T2DM is common among patients with HF, it is prudent to screen 
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patients without known T2DM in accordance with current recommendations using the 
8-hour fasting plasma glucose, 2-hour glucose tolerance test or HbA1c levels 
(equally appropriate) (82). 
Pathophysiological aspects of myocardial dysfunction in T2DM 
The most common co-existing conditions that cause HF in patients with T2DM are 
CAD and hypertension. It has also been hypothesized that T2DM-related processes 
can cause HF by directly affecting the structure and function of the heart (4). The 
major drivers of myocardial dysfunction in T2DM are insulin 
resistance/hyperinsulinemia and impaired glucose tolerance, which may be effective 
years or even decades before overt T2DM develops (83). Their detrimental effect is 
associated with numerous metabolic abnormalities such as advanced glycosylation 
end products (AGEs) deposition, lipotoxicity and microvascular rarefication (4). 
Harmful interrelations between these pathophysiologic mechanisms may exert a 
potentiating effect, leading to several maladaptive responses and resulting in 
myocyte alteration (4). Insulin resistance leads to increased free fatty acids release 
and is linked with HF-related neuroendocrine dysregulation (84). It is also an 
important etiological factor in the development of left ventricular (LV) hypertrophy 
(85), as confirmed in the Framingham study, where LV mass was significantly higher 
in female patients with T2DM compared to patients without T2DM (86). 
Hyperglycemia also exerts extensive influences on CV changes in T2DM, and can 
directly cause cardiomyocyte contractile dysfunction, mitochondrial network 
fragmentation and an increase in protein kinase C activity (87-89). Also, it causes 
activation of reactive oxygen species and the deposition of AGEs in both endothelial 
and smooth muscle cells, which predisposes to concentric LV remodeling and raises 
LV diastolic stiffness (87, 88). High myocardial free fatty acid uptake results in the 
accumulation of triglyceride in the myocardium (i.e. lipotoxicity). Cardiac steatosis, 
confirmed by proton magnetic resonance spectroscopy, is the clinical equivalent of 
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high myocardial triglyceride content and may present as LV diastolic dysfunction 
(LVDD) (90). 
Diabetic cardiomyopathy 
In 1954, Lundbæk was the first to propose the existence of a specific diabetic heart 
muscle disease without involvement of CAD or hypertension (91). Two decades later, 
Rubler described diabetic-related post-mortem findings in 4 patients with T2DM, 
glomerulosclerosis and HFrEF with normal epicardial coronary arteries (92). There is 
no definition of diabetic cardiomyopathy, which makes studies of epidemiology, 
pathophysiology, natural history and associated clinical outcomes challenging. The 
most commonly accepted definition refers to a myocardial dysfunction which occurs 
in the absence of all other CV disease (82, 93).  
Phenotypes of T2DM-related cardiomyopathy  
Left ventricular diastolic dysfunction and HFpEF in T2DM 
LVDD can be detected in 75% of T2DM patients and develops early in T2DM course, 
as confirmed by demographic characteristics of these patients, including younger 
age, normal blood pressure and optimal T2DM control (94, 95). Furthermore, the 
degree of glucose dysregulation correlates with LVDD severity (96), and with 
increased risk of incident HF and CV mortality in T2DM (97-99). Almost half of HF 
patients with T2DM have HFpEF, which is more frequent in older, hypertensive and 
female patients with T2DM and is difficult to diagnose because the symptoms are 
often mild, appear upon physical activity, and could be frequently misdiagnosed as 
chronic obstructive pulmonary disease (100).  
HFpEF is usually associated with mild T2DM complications in the early stages of 
T2DM, whilst HFrEF is associated with more severe T2DM complications (101). This 
suggests that severity and duration of hyperglycemia are important for the 
development of LV dysfunction. 
HFrEF in T2DM 
18 
 
The major cause of HFrEF in T2DM is CAD. T2DM is associated with a 2-fold higher 
risk of CAD and ischemic stroke, and a 2 to 4-fold higher CAD- and stroke-related 
mortality (102-104). CAD in T2DM is usually diffuse, multi-vessel and may lead to 
silent MI. 
 
Treatment of HF in patients with T2DM 
There are no specific constraints to HF treatment in T2DM patients as recommended 
by the ESC/HFA 2016 Guidelines for the management of HF (78). In clinical trials, all 
pharmacological and device therapies for HF were similarly effective whether or not 
patients had T2DM. Thus far, there were no clinical trials of HF treatment that 
included only patients with T2DM, and available evidence is derived from 
subanalyses of mixed populations. However, several HF drugs may exert metabolic 
effects that should be taken into account in T2DM patients. 
Pharmacological therapy 
ACE-Inhibitors 
The ESC/EASD Guidelines on diabetes, pre-diabetes, and CV diseases recommend 
ACE-inhibitors in patients with HFrEF and T2DM, as they have been shown to 
improve symptoms and reduce morbidity and mortality (78). The effectiveness of 
ACE-inhibitors in patients with both T2DM and HF, or post-MI LVSD was examined in 
a large meta-analysis of seven RCTs (105). For the end-point of all-cause mortality, 
ACE-inhibitors had a similar treatment benefit in subjects with and without T2DM 
(HR, 0.84 and 0.85, respectively).  
The only large ACE-inhibitor trial in HFrEF to provide detailed information on patients 
with T2DM was the ATLAS, which compared low-dose (2.5-5.0 mg daily) to high-
dose (32.5-35.0 mg daily) lisinopril (106, 107). The greater relative benefit for the 
composite primary endpoint (all-cause mortality or HF hospitalization) of high-dose 
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lisinopril was similar in patients with and without T2DM. However, because patients 
with T2DM were at greater risk, the absolute benefit of high-dose lisinopril was larger 
in patients with T2DM (107). The occurrence of adverse effects with high-dose 
lisinopril was similar in those with and without T2DM with respect to 
hypotension/dizziness (35% versus 32%, respectively), renal 
dysfunction/hyperkalemia (29% versus 22%) and cough (12% versus 10%) (107). 
Angiotensin Receptor Blockers 
In the CHARM trial, a significant reduction of CV death, HF hospitalization and all-
cause mortality was achieved with candesartan in patients with HF and HFrEF, 
irrespectively of T2DM (1). Also, in the Val-HeFT, valsartan treatment led to a 
significant relative risk reduction in the co-primary composite end-point (death or HF 
morbidity - mainly HF hospitalization) regardless of T2DM (108). A subsequent trial, 
HEAAL (109), showed that 150 mg daily of losartan was superior to 50 mg daily in 
reducing the risk of death or HF hospitalization, supporting the similar findings of the 
ATLAS trial with the ACE inhibitor lisinopril. The treatment effect was again not 
different in the subgroup of patients with T2DM compared to those without T2DM 
(HR, 0.96; interaction p=0.35). 
There is little information about the tolerability of ARBs in T2DM. In the overall 
CHARM program, patients with T2DM had double the risk of developing 
hyperkalemia on candesartan compared to those without T2DM (110). 
T2DM confers a higher risk of diabetic nephropathy and chronic kidney disease 
(111). Specifically, diabetic nephropathy is characterized by increased renal sodium 
retention (112, 113), and a higher risk of hyperkalemia (114). This caveat deserves 
consideration when ACE-inhibitors or ARBs are administered to diabetic patients, as 
these drugs may interfere with renal potassium excretion. Hence, monitoring of 
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serum electrolytes and creatinine is recommended when starting or escalating the 
dose of ACE-inhibitors or ARBs. 
β-blockers 
Subgroup analyses of large HF trials show that beta-blockers reduce mortality and 
hospitalization and improve symptoms in moderate to severe HF, irrespectively of 
T2DM (115)(69, 116). Beta-blockers recommended in HF and T2DM include 
metoprolol succinate (MERIT-HF) (69), bisoprolol (CIBIS II) (115) and carvedilol 
(COPERNICUS and COMET) (117, 118). The MERIT-HF reported similar efficacy 
and safety of metoprolol succinate in patients with and without T2DM (69). Adverse 
events were more often observed in T2DM patients, but were less likely to occur if 
those patients were treated with metoprolol succinate than with placebo. In a meta-
analysis of 6 trials, beta-blocker therapy reduced all-cause mortality in patients with 
T2DM (HR, 0.84) similarly to those without T2DM (HR, 0.72) (119). An analysis of 3 
trials (CIBIS II, MERIT-HF and COPERNICUS) reported a relative risk reduction for 
mortality of 0.77 in patients with T2DM and 0.65 in patients without T2DM (105). A 
third meta-analysis that focused on 7 trials using carvedilol, including a post-MI trial, 
revealed a similar, significant reduction in the risk for mortality with carvedilol in 
patients with and without T2DM (28% and 37%, respectively, interaction p=0.25) 
(120).  
Hypoglycemia is a concern in patients with T2DM treated with insulin or 
sulfonylureas. Theoretically, β-blockers could alter awareness of hypoglycemia by 
decreasing palpitations and tremor and prolong recovery from hypoglycemia by 
blocking β2 receptors, which partly control glucose production in the liver. However, 
among patients with T2DM in MERIT-HF only three (0.6%) in the placebo group and 
four (0.8%) in the metoprolol succinate group had an adverse event related to 
hypoglycaemia (in each case in patients taking insulin) (69).  
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In summary, β-blockers in patients with T2DM and HF lead to significant 
improvements in morbidity and mortality that are consistent with results in patients 
without T2DM. These treatment benefits of β-blockers in diabetic patients far 
outweigh the theoretical risks related to hypoglycaemia and minor changes in HbA1c 
and serum lipids. These benefits strongly support β-blocker treatment in patients with 
concurrent T2DM and HF. 
Mineralocorticoid receptor antagonists 
The mortality benefit of spironolactone in the RALES trial and eplerenone in the 
EMPHASIS-HF trial was consistent in T2DM and non-T2DM patients with HFrEF 
(121, 122). Importantly, eplerenone seems to have no effect on new-onset T2DM in 
patients with HF, suggesting a neutral metabolic profile (123). Caution is necessary 
when these medications are used in patients with impaired renal function and in 
those with serum potassium levels of ≥5.0 mmol/L. Monitoring of kidney function and 
potassium is mandatory since nephropathy is frequent in T2DM. Addition of an ARB 
(or renin inhibitor) to a combination of ACE-inhibitor and mineralocorticoid receptor 
antagonists is prohibited because of the increased risk of renal dysfunction and 
hyperkalemia and the lack of additional benefit (124). 
Sacubitril/valsartan 
In the PARADIGM-HF trial, sacubitril/valsartan was superior to ACE-inhibitor, 
enalapril, in reducing the risks of death and HF hospitalization (primary endpoint) in 
patients with HFrEF (50). A T2DM subgroup analysis has shown that the effect of 
sacubitril/valsartan compared with enalapril for the primary endpoint was similar in 
patients with and without T2DM (HR, 0.83 and 0.77; respectively, interaction p 
value=0.40) (36). In the post hoc analysis, treatment with sacubitril/valsartan was 
associated with a greater HbA1c reduction and a lower rate of initiation of insulin or 
other drugs for T2DM compared to enalapril (125).  
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Nitrates and hydralazine 
The A-HEFT examined the efficacy for the reduction in all-cause mortality, 
hospitalization and quality of life of a fixed dose combination of isosorbide dinitrate 
and hydralazine hydrochloride in African Americans with HF (126). A very large 
proportion (41%) of patients in the study had T2DM. The treatment effect on mortality 
was similar in patients with and without T2DM (HRs, 0.56 and 0.59, respectively). 
Ivabradine 
In a large trial involving 6558 patients with HF (30% with T2DM), ivabradine 
demonstrated a significant reduction in composite end-point of CV death or HF 
hospitalization, with no difference between T2DM and non-T2DM patients (HRs, 0.81 
and 0.83, respectively) (127).  
Diuretics 
Diuretics are usually required to treat the symptoms and signs of fluid overload in 
patients with HF. There are no clinical trials examining their efficacy in patients with 
both T2DM and HF. Theoretically thiazide diuretics can lead to increased insulin 
resistance and subsequent worsening of glycaemic control.  
Devices and surgery 
Implantable cardioverter defibrillators  
In addition to a higher risk of death due to worsening HF, patients with T2DM and HF 
are at increased risk of malignant ventricular arrhythmias and sudden cardiac death 
(SCD). In the CHARM trial, patients with T2DM experienced a significantly higher 
rate of SCD compared to patients without T2DM (40 versus 25.9 events/1000 patient 
years of follow-up), and the increased risk of SCD was observed irrespective of HF 
phenotype (i.e. HFrEF and HFpEF) (1). Observational data also demonstrate an 
increased risk of SCD in the presence of T2DM in HF of both ischemic and non-
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ischemic etiology (128). Device therapies, implantable cardioverter defibrillator (ICD) 
and cardiac resynchronization therapy with ICD (CRT-D) offer a possibility to reduce 
overall mortality with effective prevention of SCD, and data from clinical trials support 
this notion in patients with and without T2DM. 
The SCD-HeFT trial included patients with both non-ischemic and ischemic HFrEF 
who were randomized to placebo, amiodarone, or an ICD (129). The study included 
approximately 30% of patients with T2DM in every treatment arm. ICD treatment led 
to a significant relative risk reduction in death and in subgroup analysis, there were 
no interactions with T2DM. The HRs for the primary endpoint of all-cause mortality in 
ICD group were 0.95 for patients with T2DM and 0.67 for those without T2DM and in 
amiodarone group 1.2 for patients with T2DM, and for 1.0 for those without T2DM. In 
the DANISH trial, patients with non-ischaemic cardiomyopathies were randomized to 
ICD and optimal medical therapy or optimal medical therapy alone (130). 
Approximately 19% of patients had T2DM. In prespecified subgroup analysis, there 
was no significant difference in treatment effect in patients with and without T2DM 
(HRs, 0.92 and 0.85, respectively, interaction p value=0.60). 
Cardiac resynchronization therapy 
The effectiveness of CRT to reduce the risk of all-cause death and HF hospitalization 
was evaluated in 2 clinical trials (the COMPANION (131) and CARE-HF (132)) that 
randomized patients with moderate to severely symptomatic HF (NYHA class III or 
IV) to either optimal medical therapy or optimal medical therapy plus CRT. 
Additionally, two trials (MADIT-CRT (133) and RAFT (134)), randomized patients with 
mild to moderate HF symptoms to optimal medical therapy plus ICD, or optimal 
medical therapy plus CRT-D, for the primary endpoint (death or HF hospitalization). 
In relation to T2DM status, both COMPANION (41% of T2DM patients), and CARE-
HF (29% of T2DM patients) demonstrated similar effectiveness of CRT for the 
reduction in mortality and HF hospitalization (135, 136).  
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In MADIT-CRT, CRT-D treatment, compared with optimal medical therapy plus ICD, 
led to a similar reduction in the risk of all-cause death or HF hospitalization in 
patients with and without T2DM (adjusted HRs 0.56 and 0.67, respectively) (133, 
137). Also, subgroup analysis of the RAFT trial showed that the benefit of CRT-D 
was similar in patients with and without T2DM (134). Patients with T2DM did not 
experience a higher rate of complications related to device implantation, including 
infection (134). There were similar CRT-related improvements in LV volumes and 
ejection fraction in those with and without T2DM. 
Coronary artery bypass grafting 
CAD is the leading cause of premature mortality in patients with T2DM, which 
stresses the importance of an early detection (e.g. stress-echocardiography, 
coronary angiography) based on the estimated CV risk, and a timely treatment of 
CAD (138, 139). 
The STICH trial addressed the broader role of surgical revascularization in patients 
with HFrEF and less severe CAD (140). Patients suitable for surgery were 
randomized to coronary artery bypass graft (CABG) plus medical therapy or medical 
therapy alone. In the subanalysis of the STICH trial, there was no significant 
difference between patients with (40%) and without T2DM with respect to the primary 
outcome of all-cause mortality (141). This trial therefore extends the indication for 
CABG to ‘STICH-like’ patients with two- or three vessel CAD, including a left anterior 
descending stenosis, who are otherwise suitable for surgery. The benefits are similar 
whether or not a patient has T2DM. 
Exercise prescription 
Recently, a single large trial, the HF-ACTION (35), investigated the effects of 
exercise training in patients with mild to moderately severe HF symptoms. In an 
adjusted analysis, exercise training led to an 11% (p=0.03) reduction in the primary 
25 
 
composite outcome of all-cause mortality or all-cause hospitalization. The trial 
enrolled 32% of patients with T2DM and there was no interaction between T2DM 
status and the effect of exercise on clinical outcomes. 
Cardiac transplantation 
Cardiac transplantation in T2DM with macrovascular complications and end-stage 
HF may impose several challenging issues, including renal dysfunction, peripheral 
vascular disease, increased risk of infection and the need of prednisolone-based 
immunosuppression. T2DM was an independent risk factor for reduced 10-year 
survival in a large registry of 22,385 transplant patients (142). However, with modern 
immunosuppression regimens allowing more rapid tapering of steroid doses and 
steroid-free immunosuppression, cardiac transplantation in T2DM (in the absence of 
major T2DM complications) should be considered on a case-by-case basis. 
T2DM drugs and the risk of HF 
Drugs that increase HF hospitalizations 
Over the last 15 years there has been concern that some of T2DM drugs might 
increase the risk for HF (Table 7). Drugs that are now known to increase the risk for 
HF are thiazolidinediones (TZDs) and a dipeptidyl peptidase-4 (DPP4) inhibitor, 
saxagliptin (74, 143). In the RECORD (73) and the PROACTIVE trials (144), patients 
randomized to TZDs, rosiglitazone and pioglitazone, respectively, had more HF 
events than those on placebo. In the SAVOR-TIMI 33 trial (saxagliptin versus 
placebo), saxagliptin significantly increased the risk for HF hospitalizations (HR, 1.27, 
P=0.007) (74). Patients at greatest risk were those with a history of HF, an estimated 
glomerular filtration rate (eGFR) ≤60 mL/min, or elevated baseline levels of N-
terminal pro B-type natriuretic peptide (NT-proBNP) (74). In both RECORD and 
SAVOR-TIMI trials, patients who developed HF had a high rate of subsequent death. 
On that basis, pioglitazone, rosiglitazone and saxagliptin are contraindicated in 
patients with HF or at risk of HF. 
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Not all DPP4 inhibitors are associated with higher rates of HF (Table 8). In the 
EXAMINE trial of alogliptin versus placebo in patients who had had an acute 
coronary syndrome, there was not a statistically significant increase in the risk of HF 
hospitalizations in patients randomised to alogliptin (145, 146). Likewise, sitagliptin in 
the TECOS trial had no signal of excess rates of HF (147, 148). Two ongoing trials, 
CAROLINA (CV Outcome Study of Linagliptin Versus Glimepiride in Patients With 
T2DM; NCT01243424), and CARMELINA (linagliptin versus placebo in patients with 
T2DM at high vascular risk; NCT01897532), will allow further clarification on the role 
DPP4 inhibitors in patients with T2DM and HF.  
T2DM drugs that might increase the risk for HF 
Over many years there has been suspicion that insulin (which causes sodium and 
water retention) may increase the risk for the development of HF. In large 
observational studies, insulin is associated with higher mortality rates than metformin 
(2). There have been similar concerns with sulphonylureas which, as insulin 
secretagogues, have also associated with higher death rates than metformin (2). 
These studies, although large, are non-randomized and therefore inconclusive. In the 
only randomized trial of insulin versus placebo (ORIGIN - 12,537 people with CV risk 
factors plus impaired fasting glucose, impaired glucose tolerance, or T2DM [i.e. not in 
patients with HF]), insulin was not associated with higher rates of HF hospitalization 
than placebo (149). Remarkably, despite the use of insulin and sulphonylureas for 
decades there are no other placebo-controlled randomized trials. 
Currently, sulphonylureas and insulin could be used in T2DM patients with HF 
(usually as a second- or third-line treatment) although their safety in HF is still 
inconclusive. 
T2DM drugs that might be safe in HF 
It has been proposed that metformin might be safe and efficacious in patients with 
T2DM and HF. This was based on large observational studies where metformin was 
associated with lower mortality and HF hospitalization rates than other T2DM drugs 
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(primarily insulin and sulphonylureas) (2). There are no randomized trials of 
metformin in patients with T2DM and HF. Whether or not metformin is efficacious or 
safe is inconclusive. Previous concerns that metformin may cause metabolic acidosis 
are no longer justified (2). Accordingly, metformin could be recommended as the first-
line treatment for patients with T2DM and HF who have preserved or moderately 
reduced renal function (i.e. eGFR >30 mL/min). 
Glucagon-like peptide 1 (GLP1) receptor agonists have been the subject of many 
large placebo-controlled trials in patients with T2DM and CV disease or at high risk of 
CV disease (Table 8) (150-153). In these trials, GLP1 receptor agonists had a 
neutral effect on the risk for HF hospitalization. Similarly, no signal for a higher risk 
for HF hospitalization was seen with acarbose (versus placebo) in patients with 
insulin resistance and CAD (154). Bromocriptine has not been studied with respect to 
its effect on HF outcomes.  
Prevention of HF by T2DM drugs 
A significant breakthrough in contemporary cardiology was the finding that some 
T2DM drugs are associated with a lower risk of HF hospitalization in patients with CV 
disease or at high risk of CV disease (Table 8). Two large RTCs that assessed CV 
safety of the sodium-glucose co-transporter type 2 (SGLT2) inhibitors, empagliflozin 
and canagliflozin, have shown a significant reduction in HF hospitalization with both 
drugs (155, 156). The primary outcome in both trials was the 3-point major adverse 
CV event (i.e. CV death, nonfatal MI or nonfatal stroke) and HF hospitalization was a 
secondary outcome. In the EMPA-REG OUTCOME trial (n=7020), including patients 
with T2DM, established CV disease and eGFR >30 mL/min/1.73 m2, there was a 
major reduction in HF hospitalization (HR, 0.65) with empagliflozin compared with 
placebo (155). The observed beneficial effect of empagliflozin became evident early 
(i.e. 2-3 months of treatment) and was observed across a range of prespecified 
subgroups, including patients with (10%) and without investigator-reported HF at 
baseline, that had a similar reduction in HF hospitalizations with empagliflozin 
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compared with placebo. No echocardiograms or natriuretic peptide measurements 
are available from this trial, so the detail of the beneficial effect on HF hospitalization 
is not available. Patients hospitalized for HF during the study had a high mortality, 
which was lower in patients receiving empagliflozin than placebo (13.5% versus 
24.2%, respectively) (155). In the CANVAS trial, patients with T2DM (n=10,143) 
either with established CV disease or at high risk of CV disease, randomized to 
canagliflozin or placebo had a significantly lower risk of HF hospitalization (HR, 0.67) 
(156, 157). Empagliflozin in EMPA-REG Outcome, but not canagliflozin in CANVAS, 
reduced all-cause and CV mortality as well as HF hospitalization. In the EMPA-REG 
trial, the only major adverse event was an increased risk of genital tract infections, 
which were treatable, and infrequently recurred (155). In the CANVAS trial, treatment 
with canagliflozin was associated with a significantly higher risk of lower-limb 
amputations (6.3 vs. 3.4 per 1000 patient-years; HR, 1.97) and possibly a higher risk 
of fractures compared with placebo (157). Large RCTs of other new T2DM drugs 
have not shown a reduction in incident HF (Table 8).  
Treatment of HF with T2DM drugs 
Randomized clinical trials with SGLT2 inhibitors 
While two drugs (i.e. empagliflozin and canagliflozin) have a favorable effect on HF 
hospitalization, no T2DM drug has yet been investigated as a treatment for HF. In 
2017, three large RCTs with SGLT2 inhibitors (i.e. empagliflozin and dapagliflozin) 
have started, which will enroll HF patients either with or without T2DM (i.e. T2DM is 
not a mandatory inclusion criteria). Two trials will assess safety and efficacy of 
empagliflozin versus placebo on top of guideline-based medical therapy for the 
reduction in primary outcome (CV death or HF hospitalization) both in patients with 
HFrEF (EMPEROR-Reduced, NCT03057977) and HFpEF (EMPEROR-Preserved, 
NCT03057951) (Table 9). Among secondary outcomes, the two trials will assess all-
cause mortality, and renal effects of empagliflozin versus placebo in patients with HF. 
The third trial, Dapa-HF (NCT03036124), will assess safety and efficacy of 
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dapagliflozin versus placebo for the reduction in CV death or HF hospitalization (or 
urgent HF visit) in patients with HFrEF. Secondary outcomes will include all-cause 
mortality and effects on renal function. The results of these trials will shed more light 
on the beneficial CV and renal effects of SGLT2 inhibitors in HF patients, including 
those without T2DM. 
In addition, a number of ongoing smaller randomized trials are assessing the effect of 
SGLT2 inhibitors on CV outcomes, including various aspects of HF in patients with 
and without T2DM, as summarized in Table 9.  
Randomized clinical trials with GLP1 receptor agonists 
In the LIVE trial, in patients with stable HFrEF, with and without T2DM, there were no 
significant changes in LVEF between patients randomized on liraglutide or placebo 
(158). However, there was a significant increase in heart rate (P<0.0001) and more 
serious cardiac adverse events with liraglutide (P=0.04). In a placebo-controlled 
FIGHT trial, of patients with HFrEF, with and without T2DM (41%), liraglutide was not 
associated with an improvement in a composite primary end point of death, 
rehospitalization and NT-proBNP change (159). Prespecified subgroup analyses in 
patients with T2DM did not reveal any significant between-group differences. A small 
randomized, placebo-controlled trial of albiglutide in HFrEF showed no effect on LV 
function and 6-minute walk distance (160). These observations have raised some 
concern regarding the safety of liraglutide in HFrEF patients that warrant further 
research. 
Conclusions 
T2DM and HF are both common and frequently coexist. The causes of HF in T2DM 
are numerous, but CAD and hypertension are likely the most important contributors 
to concurrent T2DM and HF, whereas a direct effect of T2DM on the myocardium 
(e.g. “diabetic cardiomyopathy”) might also play a role. Evidence from recent large-
scale clinical trials and registries indicates a significantly higher risk of adverse 
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outcomes in patients with HF and T2DM, including a higher risk for hospitalization 
and rehospitalization for HF, as well as increased all-cause and CV mortality, 
independent of HF etiology or phenotype (i.e. HFrEF and HFpEF). HF treatment with 
medications and devices (e.g. ICD, CRT-D) is similarly effective in patients with and 
without T2DM. There has been uncertainty about the safety of older T2DM drugs 
such as insulin and sulphonlyureas in patients with T2DM and HF but there are no 
randomized controlled trials to allow firm conclusions. In patients with T2DM without 
HF, some drugs have been shown to increase the risk of HF hospitalizations (i.e. 
rosiglitazone, pioglitazone and saxaglitpin) and, consequently, these medications are 
contraindicated in patients T2DM with prior HF or at risk of HF. Large clinical trials 
investigating CV safety of newer antidiabetic drugs in patients with CV disease or at 
high CV risk have demonstrated that GLP1 receptor agonists and a DPP4 inhibitor, 
sitagliptin, have a neutral effect on the risk of HF hospitalisations. In addition, SGLT2 
inhibitors, empagliflozin and canagliflozin demonstrated a significant reduction in the 
risk of HF hospitalizations in patients with T2DM. SGLT2 inhibitors are currently 
beeing investigated as a potential addition to the optimal medical treatment of HF, 
not only in patients with, but also in those without T2DM.  
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Tables 
Table 1.  Prevalence of HF in selected trials of T2DM drugs 
Trial Prevalence of HF at baseline 
Glucose-lowering trials 
UKPDS (161) 
NR 
(severe concurrent illness excluded) 
 
ADVANCE (162, 163) 
NR  
 
ACCORD (164) 
4.3% 
 
VADT (165) 
NR 
 
DPP4 inhibitors trials 
SAVOR-TIMI 53 (74, 143) 
13% 
 
TECOS (147) 
18% 
 
EXAMINE (145) 
28% 
 
SGLT2 inhibitors trials 
EMPA-REG OUTCOME (155) 
10% 
 
CANVAS (157) 
14-15% 
 
GLP1 receptor agonists trials  
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LEADER (152) 
14% 
 
ELIXA (153) 
22% 
 
EXSCEL (150) 
16% 
 
DPP4 - dipeptidyl peptidase-4; SGLT2 - sodium glucose cotransporter type-2; GLP1 - 
glucagon like peptide-1 
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Table 2. The prevalence of T2DM in patients with HF in the general population 
Study 
Year of 
publication 
Age range 
(years) 
Prevalence of 
T2DM in HF 
Prevalence of 
T2DM without HF 
England (12) 2001 >45 24% 3% 
Rotterdam (41) 
 
2001 55-94 18% 10% 
Italy (11) 1997 >65 30% 13% 
Reykavik (9) 2005 33-84 12% 3% 
Copenhagen 
(13) 
2005 mean age 69 25% NA 
USA, 
Olmsted 
county (57) 
2006 mean age 77 20% NA 
NA - Not available (cohort of HF patients only) 
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Table 3. The prevalence of T2DM in selected trials of HF 
Trial  Prevalence of T2DM 
Trials of HFrEF 
PARADIGM (50) 
 
35% 
SHIFT (166) 
 
30% 
ECHO-CRT (51) 
 
41% 
HF-ACTION (35) 
 
32% 
SENIORS (167) 
 
26% 
SOLVD (168) 
 
15% 
MERIT-HF (69) 25% 
CHARM-added (169) 
 
29% 
DIG-REF (170) 
 
28% 
Trials of HFpEF 
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I-PRESERVE (39) 
 
 
27% 
PEP-CHF (171) 
 
21% 
DIG-PEF (172) 
 
29% 
CHARM-preserved (173) 
 
28% 
TOPCAT (174) 
 
33% 
Trials of acute HF 
EVEREST (48) 
 
 
39% 
TRUE-HF (175) 
 
39% 
ASCEND (176) 
 
42.6% 
RELAX-AHF (177) 47% 
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HFrEF - heart failure with reduced ejection fraction; HFpEF - heart failure with preserved 
ejection fraction. 
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Table 4. T2DM and mortality in HF in population studies, outpatient clinics and hospitalized patients 
Country 
(region) 
Year of 
publication 
 
Type of study 
Total 
number of 
patients 
Number of 
patients with 
T2DM 
Adjusted all-cause 
mortality risk of T2DM  
Adjusted CV mortality risk of 
T2DM   
Population-
based 
studies 
      
ESC-HF-Long 
term Registry 
(17) 
2017 Population-based 9428 3440 1.28 (1.07–1.54) 1.28 (0.99–1.66) 
ESC-HF-Long 
term Registry 
(49) 
2017 Population-based 6926 3422 1.77 (1.28–2.45) NA 
Swedish HF 
Registry (178) 
2014 
Population and 
specialist 
outpatient- based 
36454 8809 1.60 (1.50-1.71) NA 
United States 
(Olmsted)  
(57) 
2006 Population-based 665 128 
1.48 (1.20-1.82) 
 
NA 
Netherlands 
(Rotterdam)  
(41) 
2001 Population-based 5540 557 3.19 (1.80–5.65) 
3·25 (1·53–6·93) 
(Sudden cardiac death 3·65 
(1·28–10·4) 
Outpatient 
clinics 
      
UK (128) 2013 Cardiology clinics 1091 280 2.08 (1.61 2.69) NA 
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USA (179, 
180) 
2005 HF clinic 495 293 1.71 (1.16–2.51) NA 
Italy (181) 2003 
Outpatient Registry 
‘BRING-UP’ 
2843 621 1.44 (1.16–1.78) NA 
Hospitalized 
patients 
      
Spain (71) 
(RICA 
Registry) 
2014 
Hospitalized 
multicenter registry 
1082 490 1.54 (1.20–1.97) NA 
Spain INCAex 
(182) 
2013 
Hospitalized single 
center 
1659 Not stated 1.35 (1.11 to 1.66) NA 
USA - 
MEDICARE 
(183) 
1999 
Hospitalization-
based 
 
170239 NA 
Black: 1.11 (1.06–1.16) 
White: 1.22 (1.24–1.25) 
NA 
HR - Hazard Ratio; NA – not available 
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Table 5. T2DM and all-cause mortality in clinical trials with HF 
Clinical trial Year trial 
published 
Treatment Total number 
of patients 
 
Number of 
patients with 
T2DM 
Adjusted all-cause mortality 
risk of T2DM  
Adjusted CV mortality risk of 
T2DM  
HFrEF  trials       
PARADIGM-
HF (50) 
2015 sacubitril/ 
valsartan 
8399 
 
2907 1.46 (1.26–1.70) 
 
1.54 (1.30–1.83) 
 
SHIFT (166) 2010 ivabradine 6505 1979 1.10 (0.96–1.25) 
 
1.05 (0.91–1.20) 
Mortality due to HF 
1.15 (0.88–1.49) 
ECHO-CRT 
(51) 
2013 CRT 809 328 2.08 (1.29, 3.36) 
 
1.79 (1.06, 3.03) 
Mortality due to HF 
2.45 (1.03, 5.78) 
HF-ACTION 
(35) 
2016 exercise 2331 748 0.97 (0.78, 1.2) NA 
SENIORS 
(167) 
2010 nebivolol 2128 555 1.25 (0.99–1.58) NA 
SOLVD (184) 1996 enalapril 4223 647 1.29 (1.1–1.5) 
 
NA 
MERIT-HF 
(69) 
2005 metoprolol 3991 985 1.08 (0.80-1.47) NA 
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CHARM (1) 2008 candesartan 4576 1306 1.55 1.54 
HFpEF trials       
DIG -
preserved 
(172) 
2010 digoxin 987  1.48 (1.10- 1.99) NA 
I-PRESERVE 
(185) 
2017 irbesartan 4128 1134 1.59 (1.33–1.91) 1.59 (1.28–1.96) 
CHARM (1, 
186) 
2008 candesartan 3023 857 1.84 1.93 
TOPCAT 
(174) 
2017 spironolactone 3385 1109 without microvascular 
complications: 
HR 1.51, 95% CI 1.14, 1.99; 
with microvascular 
complications: 
HR 1.35, 95% CI 1.04, 1.75 
NA 
Acute HF 
trials 
      
EVEREST 
(48, 187) 
2013 tolvaptan 4133 1657 1.16 (1.00–1.34) NA 
HFrEF - heart failure with reduced ejection fraction; NA – not available; HFpEF - heart failure with preserved ejection fraction.  
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Table 6. T2DM and all-cause mortality in heart failure: ischemic versus non-ischemic etiology 
Location 
Year of 
publication 
 
Type of study 
Number of 
patients 
Number of 
patients 
with T2DM 
Adjusted all-cause mortality risk 
of T2DM 
ischemic vs. non-ischemic 
etiology 
Adjusted CV mortality risk of T2DM 
ischemic vs. non- ischemic 
etiology 
Population 
studies 
and HF 
clinics 
      
Denmark 
(55) 
2009 
Population-based 
cohort 
2621 420 
HF secondary to CAD: 
1.45 (1.22–1.73) 
 
HF secondary to other etiologies 
1.50 (1.22–1.84) 
NA 
Olmsted, 
USA (57) 
2006 
Population-based 
cohort study 
665 128 
HF secondary to CAD: 
1.11 (0.81–1.51) 
 
HF secondary to other etiologies: 
1.79 (1.33–2.41) 
NA 
France (58) 2004 HF clinic 1246 274 
HF secondary to CAD 
1.54 (1.13–2.09) 
 
NA 
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HF secondary to other etiologies: 
0.65 (0.39–1.07) 
Clinical 
trials 
 Drug     
SOLVD (60, 
184) 
1996 enalapril 4223 647 
HF secondary to CAD: 
1.37 (1.21–1.55) 
 
HF secondary to other etiologies: 
0.98(0.76–1.32) 
NA 
BEST (53) 2003 bucindolol 2708 964 
HF secondary to CAD: 
1.33 (1.12–1.58) 
HF secondary to other etiologies: 
0.98 (0.74–1.30) 
NA 
DIG (188) 2004 digoxin 4277 NA 
HF secondary to CAD: 1.43 
(1.26–1.63) 
HF secondary to other etiologies: 
HR not stated 
NA 
CV - cardiovascular; CAD - coronary artery disease; NA – not available 
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Table 7. Summary of evidence for T2DM drugs in patients with prevalent HF  
Class of drug Evidence 
 
SGLT-2 inhibitors 
(e.g. empagliflozin, canagliflozin) 
No RCTs in HF 
Large RCTs in patients with HF with an without T2DM are underway 
Metformin 
No RCTs in HF 
In observational studies in HF metformin is associated with lower mortality rates than 
sulphonylureas or insulin (189). 
Benefit/ risk unknown 
GLP-1 receptor antagonists (eg 
liraglutide, albiglutide) 
No large RCTs 
liraglutide - 2 small RCTs reported no effect on i) LV function (158) ii) hierarchical composite of death/ HF 
hospitalization/ BNP change (159) 
Benefit/ risk unknown 
Sulphonylureas 
No RCTs in HF 
Data Equivocal. Some observational data suggest an increased mortality risk with sulphonylureas compared 
with metformin (189, 190). 
Insulin 
No RCTs in HF 
In observational studies in HF insulin was associated with higher mortality rates than metformin (189). 
Benefit/ risk unknown 
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DPP4 inhibitors 
No RCTs in HF 
(saxagliptin contra-indicated in HF (74, 143)) 
Benefit/ risk unknown 
SGLT2 - sodium glucose cotransporter type 2; RCT - randomized clinical trials; GLP1 - glucagon-like peptide 1; LV - left ventricular; DPP4 - dipeptidyl 
peptidase-4 
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Table 8. HF outcomes in published large cardiovascular outcome trials in patients withT2DM  
Study 
SAVOR TIMI 53 (74, 
143) 
EXAMINE (145, 146) 
TECOS (147, 
148) 
  
DPP4 inhibitor saxagliptin alogliptin sitagliptin   
comparator placebo placebo placebo   
results 
increase in HF 
hospitalization 
no statistically significant 
increase in HF 
hospitalization 
no effect on HF 
hospitalization 
  
Study ELIXA (150) LEADER (152) 
SUSTAIN 6 
(151) 
 EXSCEL (150) 
GLP1 receptor agonists lixisenatide liraglutide semaglutide  exenatide 
 
exenatide 
comparator placebo placebo placebo   
results 
no effect on HF 
hospitalization 
no effect on HF 
hospitalization 
no effect on HF 
hospitalization 
 
no effect on HF 
hospitalization 
Study 
EMPA-REG 
OUTCOME (155) 
CANVAS (157)    
SGLT-2 inhibitor empaglifozin canagliflozin    
comparator placebo placebo    
results 
reduced HF 
hospitalization 
reduced HF 
hospitalization 
   
 
DPP4 - dipeptidyl peptidase-4; GLP1 - glucagon-like peptide 1; SGLT2 - sodium glucose cotransporter type 2 
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Table 9. Selected ongoing randomized clinical trials of SGLT2 inhibitors in patients with prevalent HF 
Clinical trial  Brief description of the trial  
EMPAGLIFLOZIN  
EMPEROR-
Reduced 
(NCT03057977) 
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction. 
 Study population: HFrEF, with and without T2DM. 
 Estimated enrolment: n= 2850. 
 Treatment: empagliflozin vs. placebo on top of guideline-based medical therapy. 
 Primary outcome: CV death or HF hospitalisation (Time Frame: up to 38 months). 
EMPEROR-
Preserved 
(NCT03057951) 
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction 
 Study population: HFpEF, with and without T2DM. 
 Estimated enrolment: n= 4126. 
 Treatment: empagliflozin vs. placebo on top of guideline-based medical therapy. 
 Primary outcome: CV death or HF hospitalisation (Time Frame: up to 38 months). 
Empire HF 
(NCT03198585) 
Empagliflozin in HF Patients With Reduced Ejection Fraction 
 Study population: HFrEF, with and without T2DM. 
 Estimated enrolment: n=189. 
 Treatment: empagliflozin vs. placebo on top of guideline-based medical therapy. 
 Primary outcome: Change in plasma concentrations of NT-proBNP (Time Frame: 90 days) as a measure of treatment impact 
on HF 
EMMY 
(NCT03087773) 
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction 
 Study population: patients with acute MI with and without T2DM. 
 Estimated enrolment: n=476. 
 Treatment: empagliflozin vs. placebo. 
 Primary outcome: change in plasma concentrations of NT-proBNP (Time Frame: 26 weeks) as a measure of treatment impact 
on HF 
RECEDE-CHF SGLT2 Inhibition in Combination With Diuretics in HF. 
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(NCT03226457)  Study population: HFrEF with T2DM. 
 Estimated enrolment: n=34. 
 Treatment: empagliflozin vs. placebo. 
 Primary outcome: the effect on the change in urine output from baseline (Time Frame: 6 weeks). 
CANAGLIFLOZIN  
NCT02920918 Treatment of DM in patients with systolic HF 
 Study population: HFrEF with T2DM. 
 Estimated enrolment: n=88. 
 Treatment: canagliflozin vs. sitagliptin. 
 Primary outcome: change in aerobic exercise capacity and ventilator efficiency (Time Frame: baseline and 12 weeks) 
DAPAGLIFLOZIN  
Dapa-HF 
(NCT03036124) 
Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic HF. 
 Study population: HFrEF with and without T2DM 
 Estimated enrolment: n=4500. 
 Treatment: dapagliflozin vs. placebo. 
 Primary outcome: CV death or hospitalization for HF, or an urgent HF visit (Time Frame: from randomization up to 
approximately 3 years). 
DEFINE-HF 
(NCT02653482) 
Effects on symptoms and biomarkers of HF in patients HFrEF 
 Study population: HFrEF with T2DM. 
 Estimated enrolment: n=250. 
 Treatment: dapagliflozin vs. placebo. 
 Primary outcome: change in plasma concentrations of NT-proBNP (Time Frame: 12 weeks) as a measure of treatment impact 
on HF 
PRESERVED-HF 
(NCT03030235) 
 
Dapagliflozin Effect on Symptoms and Biomarkers in patients HFpEF 
 Study population: HFpEF with T2DM or prediabetes. 
 Estimated enrolment: n=320. 
 Treatment: dapagliflozin vs. placebo. 
 Primary outcome: change in plasma concentrations of NT-proBNP (Time Frame: Baseline to Week 6 and Week 12) as a 
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measure of treatment impact on HF 
REFORM 
(NCT02397421) 
Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes 
 Study population: HFrEF with T2DM. 
 Estimated enrolment: n=56. 
 Treatment: dapagliflozin vs. placebo. 
 Primary outcome: changes in LV systolic and diastolic volumes in patients as determined by cardiac magnetic resonance 
imaging. 
CV - cardiovascular, NT-proBNP  - N-terminal pro B-type natriuretic; MI - myocardial infarction; SGLT2 - sodium glucose cotransporter type 2; LV - left 
ventricular  
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